IP Library Granted Patent US 8,079,998
Granted Patent B2
US 8,079,998 · App. 11/713,344 · Granted Dec 20, 2011

Methods and devices for the delivery of therapeutic gases including nitric oxide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,079,998
App. No.
11/713,344
Granted
Dec 20, 2011
Kind
B2
Abstract

Gas packages for the delivery of therapeutic gases, and in particular gaseous nitric oxide (gNO) are provided herein. The gas packages comprise one or more of a gas reservoir, interface layer, sealing layer, and holding container. The interface layer regulates discharge of the therapeutic gas from the gas reservoir to the external environment. The sealing layer and/or holding container prevent evolution of the gas until the sealing layer is compromised or the holding container is opened. The gas packages and methods for using them are useful for the treatment, alleviation, and prevention of various disease and non-disease, medical and non-medical, conditions in humans and animals.

Claims (23)

1. A method of administering one or more therapeutic gases to an animal or human patient, comprising:

providing at least one device comprising a reservoir that is capable of supplying the one or more therapeutic gases, an interface layer, made of a gas permeable material surrounding the reservoir, through which the gases must transit in order to reach the patient,

and an element, covering all or some of the interface layer, that prevents the flow of therapeutic gases through the interface layer to the patient until the at least one device is activated, and that is selected from the group consisting of a sealing layer, a holding container, and combinations thereof;

activating the at least one device by compromising the element; and

allowing the one or more therapeutic gases to transit from the reservoir through the interface layer to the patient.

2. The method of claim 1 , wherein the one or more therapeutic gases are selected from the group consisting of gaseous nitric oxide (gNO), oxygen (O 2 ), carbon monoxide (CO), nitrogen (N 2 ), and nitrous oxide (N 2 O).

3. The method of claim 2 , wherein the one or more therapeutic gases is gaseous nitric oxide (gNO).

4. The method of claim 1 , further comprising selecting the interface layer on the basis of one or more factors selected from the group consisting of the partial pressure of therapeutic gases in the reservoir, the concentration of the one or more therapeutic gases in the reservoir, and a desired delivery rate of the one or more therapeutic gases to the animal or human patient.

5. The method of claim 1 , wherein the one or more therapeutic gases are administered to a situs on or in the animal or human patient selected from the group consisting of the mouth, teeth, gums, anus, vagina, nose, ears, eyes, and skin.

6. The method of claim 1 , wherein the one or more therapeutic gases are administered into a protective suit and subsequently inhaled by the animal or human patient.

7. The method of claim 1 , wherein the one or more therapeutic gases are administered into a protective suit and subsequently absorbed into the animal or human patient's skin.

8. The method of claim 1 , wherein the one or more therapeutic gases are administered into a breathing apparatus and subsequently inhaled by the animal or human patient.

9. The method of claim 1 , wherein the one or more therapeutic gases treat a disease or non-disease state in the animal or human patient selected from the group consisting of: vasodilatation; bacterial, viral, and fungal infections; biofilms; respiratory conditions; respiratory, airway, eye, and ear infections;

wound infections; burns; cancer; cosmetic conditions; topical conditions; skin and tissue conditions; blood conditions; inflamation; bronchoconstriction; reversible pulmonary vasoconstriction; asthma; pulmonary hypertension; adult respiratory distress syndrome (ARDS); and persistent pulmonary hypertension of the newborn (PPHN).

10. The method of claim 1 , wherein the one or more therapeutic gases prevent a disease or non-disease state in the animal or human patient selected from the group consisting of vasodilatation; bacterial, viral, and fungal infections; biofilms; respiratory conditions; respiratory, airway, eye, and ear infections; wound infections; burns; cancer; cosmetic conditions; topical conditions; skin and tissue conditions; blood conditions; inflamation; bronchoconstriction; reversible pulmonary vasoconstriction; asthma; pulmonary hypertension; adult respiratory distress syndrome (ARDS); and persistent pulmonary hypertension of the newborn (PPHN).

11. A method of treating or preventing disease and non-disease states in an animal or human patient, comprising administering one or more therapeutic gases to the patient by activating one or more gas package devices, wherein at least one gas package device comprises:

a reservoir that is capable of supplying the one or more therapeutic gases;

an interface layer, made of a gas permeable material surrounding the reservoir, that regulates the flow of the one or more therapeutic gases from the reservoir to an environment external to the at least one device; and

an element, covering all or some of the interface layer, that prevents the flow of therapeutic gases through the interface layer to the external environment until the at least one device is activated by compromising the element, and that is selected from the group consisting of a sealing layer, a holding container, and combinations thereof.

12. The method of claim 11 , wherein the disease and non-disease states are selected from the group consisting of: vasodilatation; bacterial, viral, and fungal infections; biofilms; respiratory conditions; respiratory, airway, eye, and ear infections; wound infections; burns; cancer; cosmetic conditions; topical conditions; skin and tissue conditions; blood conditions; inflammation; bronchoconstriction; reversible pulmonary vasoconstriction; asthma; pulmonary hypertension; adult respiratory distress syndrome (ARDS); and persistent pulmonary hypertension of the newborn (PPHN).

13. The method of claim 11 , wherein the one or more therapeutic gases are selected from the group consisting of gaseous nitric oxide (gNO), oxygen (O 2 ), carbon monoxide (CO), nitrogen (N 2 ), and nitrous oxide (N 2 O).

14. The method of claim 13 , wherein the one or more therapeutic gases is gaseous nitric oxide (gNO).

15. The method of claim 11 , wherein the one or more therapeutic gases is delivered to a situs on or in the animal or human patient selected from the group consisting of the skin, respiratory airways, upper nasal system, sinuses, eyes, rectum, vagina, face, and mouth.

Assignments (6)
SECURITY INTEREST Recorded Nov 24, 2025
From: BEYOND AIR LTD
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 073017/0112 →
CHANGE OF NAME Recorded Aug 12, 2022
From: ADVANCED INHALATION THERAPIES (AIT) LTD.
To: BEYOND AIR LTD
Reel/Frame 061164/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2018
From: AIT THERAPEUTICS, INC.
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 047562/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2018
From: ADVANCED INHALATION THERAPIES (AIT) LTD.
To: AIT THERAPEUTICS, INC.
Reel/Frame 046234/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: PULMONOX TECHNOLOGIES CORPORATION
To: ADVANCED INHALATION THERAPIES (AIT) LTD.
Reel/Frame 043779/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2007
From: HOLE, DOUGLAS R.; FIGLEY, CURTIS; LEE, ROBERT E.; HUDEC, MICHAEL; ROLFSON, ROBERT
To: PULMONOX TECHNOLOGIES CORPORATION
Reel/Frame 019244/0755 →